Current concepts of procainamide therapy

Paul E Fenster, F. I. Marcus

Research output: Contribution to journalArticle

Abstract

Procainamide is an effective agent for suppressing ventricular and supraventricular dysrhythmias, and recent investigations reveal that a metabolite, N-acetylprocainamide (NAPA), also has antidysrhythmic action. NAPA, which is excreted unchanged by the kidney, is found in high concentrations in the plasma of patients with renal failure. Further, procainamide may induce a systemic lupus erythematosus-like reaction in some chronic users, and the ratio of plasma procainamide to NAPA in patients on procainamide may by predictive of the risk of developing this immunologic reaction. These recent investigations have enhanced our ability to use procainamide more safely and more effectively.

Original languageEnglish (US)
Pages (from-to)1013-1021
Number of pages9
JournalCardiovascular Medicine
Volume4
Issue number9
StatePublished - 1979

Fingerprint

Procainamide
Acecainide
Therapeutics
Systemic Lupus Erythematosus
Renal Insufficiency
Kidney

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Current concepts of procainamide therapy. / Fenster, Paul E; Marcus, F. I.

In: Cardiovascular Medicine, Vol. 4, No. 9, 1979, p. 1013-1021.

Research output: Contribution to journalArticle

Fenster, PE & Marcus, FI 1979, 'Current concepts of procainamide therapy', Cardiovascular Medicine, vol. 4, no. 9, pp. 1013-1021.
Fenster, Paul E ; Marcus, F. I. / Current concepts of procainamide therapy. In: Cardiovascular Medicine. 1979 ; Vol. 4, No. 9. pp. 1013-1021.
@article{4c774f936a3e449f98647aaa307b1c10,
title = "Current concepts of procainamide therapy",
abstract = "Procainamide is an effective agent for suppressing ventricular and supraventricular dysrhythmias, and recent investigations reveal that a metabolite, N-acetylprocainamide (NAPA), also has antidysrhythmic action. NAPA, which is excreted unchanged by the kidney, is found in high concentrations in the plasma of patients with renal failure. Further, procainamide may induce a systemic lupus erythematosus-like reaction in some chronic users, and the ratio of plasma procainamide to NAPA in patients on procainamide may by predictive of the risk of developing this immunologic reaction. These recent investigations have enhanced our ability to use procainamide more safely and more effectively.",
author = "Fenster, {Paul E} and Marcus, {F. I.}",
year = "1979",
language = "English (US)",
volume = "4",
pages = "1013--1021",
journal = "Cardiovascular Medicine",
issn = "0199-6614",
number = "9",

}

TY - JOUR

T1 - Current concepts of procainamide therapy

AU - Fenster, Paul E

AU - Marcus, F. I.

PY - 1979

Y1 - 1979

N2 - Procainamide is an effective agent for suppressing ventricular and supraventricular dysrhythmias, and recent investigations reveal that a metabolite, N-acetylprocainamide (NAPA), also has antidysrhythmic action. NAPA, which is excreted unchanged by the kidney, is found in high concentrations in the plasma of patients with renal failure. Further, procainamide may induce a systemic lupus erythematosus-like reaction in some chronic users, and the ratio of plasma procainamide to NAPA in patients on procainamide may by predictive of the risk of developing this immunologic reaction. These recent investigations have enhanced our ability to use procainamide more safely and more effectively.

AB - Procainamide is an effective agent for suppressing ventricular and supraventricular dysrhythmias, and recent investigations reveal that a metabolite, N-acetylprocainamide (NAPA), also has antidysrhythmic action. NAPA, which is excreted unchanged by the kidney, is found in high concentrations in the plasma of patients with renal failure. Further, procainamide may induce a systemic lupus erythematosus-like reaction in some chronic users, and the ratio of plasma procainamide to NAPA in patients on procainamide may by predictive of the risk of developing this immunologic reaction. These recent investigations have enhanced our ability to use procainamide more safely and more effectively.

UR - http://www.scopus.com/inward/record.url?scp=0018670047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018670047&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0018670047

VL - 4

SP - 1013

EP - 1021

JO - Cardiovascular Medicine

JF - Cardiovascular Medicine

SN - 0199-6614

IS - 9

ER -